騰盛博藥-B(02137.HK)2023年度研發開支4.03億元 將積極尋求外部合作
格隆匯3月22日丨騰盛博藥-B(02137.HK)公吿,截至2023年12月31日止年度,其他收入為人民幣163.7百萬元,與截至2022年12月31日止年度的人民幣107.9百萬元相比,增加人民幣55.8百萬元或51.7%。這主要是由於美元及港元定期存款利率上升導致銀行利息收入增加人民幣70.8百萬元。該增加部分被中國政府補助確認的收入減少所抵銷。
截至2023年12月31日止年度,研發開支為人民幣402.7百萬元,與截至2022年12月31日止年度的人民幣440.6百萬元相比,減少人民幣37.9百萬元或8.6%。該減少主要是由於COVID-19項目終止。
展望未來,公司準備為其HBV功能性治癒項目啟動後期臨牀試驗,同時考慮科學差異化、商業化步伐及達到同類最佳療效的潛力等因素。此外,公司將積極尋求外部合作,以推進公司的MDR/XDR、HIV及CNS項目的臨牀開發,同時亦專注於PreHevbriTM在亞太地區的商業化。此外,公司正在努力完善公司的研發策略,高度重視與公司的長期管線利益、優先事項及戰略目標相一致的平台及疾病領域。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.